InvestorLens

RYTM — RHYTHM PHARMACEUTICALS INC

Public company

Sign in to save4 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

Why are billionaires buying RYTM?

Built from public SEC filings and public economic data. Not a recommendation.

Confidence
95
Institutional Conviction
Strong distribution · 0 buying vs 1 selling last quarter
8
Macro Tailwind
Macro conditions are mixed for this sector
52
Why? — Evidence & Confidence ▾

Of 1 tracked investors who changed their RYTM position last quarter, 0 bought and 1 sold (0% buy-side). Macro conditions are mixed for this sector (Macro Tailwind 52/100 in a Squeeze regime).

Supporting evidence
  • +4 tracked investors reported holding RYTM at their latest filing
Contradicting evidence — always shown
  • −1 tracked investor reduced or exited last quarter (0 reduced, 1 sold out)
  • −13F data is disclosed up to 45 days after quarter end — positions may have changed since
Know the limits
  • · 13F disclosure lag (up to 45 days)
  • · Tracked investors are a sample, not the whole market
  • · Sector regime fit is a historical average, not a guarantee

Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 8/4/2026.

About RHYTHM PHARMACEUTICALS INC (RYTM)

RHYTHM PHARMACEUTICALS INC (RYTM) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $126M. Across recent filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 exited. All data sourced from SEC 13F filings.

Smart Money Consensus™

Based on recent institutional activity in RYTM

50
/100
Mixed Activity
Added / Increased1
Reduced0
Exited1
BearishBullish
Crowded Trade Score™

How many top investors track RYTM

27
/100
Emerging Interest
4investors

A small number of top investors own this.

UndiscoveredCrowded
151015+

RYTM Ownership Composition

How RHYTHM PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.

Dominant Type
Other
69% of tracked value
Institutions
4
tracked investors
Total Reported
$241M
combined 13F value
Sectors2
  • Other69.4%
  • Hedge Funds30.6%
Other(3)
69.4%
Hedge Funds(1)
30.6%

Tracked investors reporting RYTM

  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    1.5M
    Value
    $126.4M
    % Portfolio
    0.02%
  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    846.8K
    Value
    $73.6M
    % Portfolio
    0.09%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    451.8K
    Value
    $39.3M
    % Portfolio
    0.02%
  • Paul Tudor JonesMar 31, 2026
    Tudor Investment Corp
    Shares
    19.6K
    Value
    $1.7M
    % Portfolio
    0.00%

Recent activity

Frequently asked questions

How many institutional investors hold RYTM?
4 tracked institutional investors disclosed a position in RYTM (RHYTHM PHARMACEUTICALS INC) in their most recent 13F filing.
Who is the largest institutional holder of RYTM?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in RYTM, valued at $126M.
Did institutional ownership of RYTM increase or decrease?
Across recent 13F filings, tracked investors recorded 1 new positions, 0 increased, 0 reduced, and 1 fully exited RYTM.
Where does this RYTM ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.